Clinical Trials Browser

Completed × Has results × parsaclisib × Clear all

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Phase 2 Completed

60 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Phase 2 Completed

110 enrolled 18 charts

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT03235544 2025-03-18

(CITADEL-205)

Phase 2 Completed

162 enrolled 18 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03126019 2025-03-14

CITADEL-203

Phase 2 Completed

126 enrolled 15 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT04434937 2024-10-23

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Phase 2 Completed

42 enrolled 13 charts

Lymphoma, Lymphoma, Follicular

NCT02018861 2023-09-28

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Phase 1/2 Completed

88 enrolled 25 charts

B-Cell Malignancies